Psychiatry

Back to articles

Opioid Dependency Shifting to Office-Based Care

KEY POINT

After a long delay, FDA has finally approved high-potency sublingual tablets of buprenorphine for long- term treatment of opioid dependency. American physicians who receive or have appropriate education and obtain a spe- cial Drug Enforcement Administration (DEA) number are now able to treat in their offices patients who previously had to seek care at methadone clinics.

SOURCES

Fiellin DA, O’Connor PG. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002;347:817–23.

Boatwright DE. Buprenorphine and addiction: challenges for the pharmacist. J Am Pharm Assoc. 2002;42:432–8.

Food and Drug Administration. Information for pharmacists—Suboxone and Subutex. Available at: www.fda.gov/cder/drug/infopage/subutex_suboxone/default.htm. Accessed October 9, 2002.